- Home
- ARGX vs EXC Comparison
ARGX vs EXC Comparison
Compare ARGX & EXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- EXC
- Stock Information
- Founded
- ARGX 2008
- EXC 1999
- Country
- ARGX Netherlands
- EXC United States
- Employees
- ARGX N/A
- EXC N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- EXC Power Generation
- Sector
- ARGX Health Care
- EXC Utilities
- Exchange
- ARGX Nasdaq
- EXC Nasdaq
- Market Cap
- ARGX 45.1B
- EXC 45.5B
- IPO Year
- ARGX 2017
- EXC N/A
- Fundamental
- Price
- ARGX $791.72
- EXC $45.41
- Analyst Decision
- ARGX Strong Buy
- EXC Hold
- Analyst Count
- ARGX 19
- EXC 11
- Target Price
- ARGX $793.06
- EXC $46.91
- AVG Volume (30 Days)
- ARGX 363.7K
- EXC 5.9M
- Earning Date
- ARGX 10-30-2025
- EXC 11-04-2025
- Dividend Yield
- ARGX N/A
- EXC 3.53%
- EPS Growth
- ARGX N/A
- EXC 8.94
- EPS
- ARGX 18.75
- EXC 2.64
- Revenue
- ARGX $3,120,821,000.00
- EXC $23,766,000,000.00
- Revenue This Year
- ARGX $80.01
- EXC $5.45
- Revenue Next Year
- ARGX $30.64
- EXC $2.90
- P/E Ratio
- ARGX $38.08
- EXC $17.20
- Revenue Growth
- ARGX 88.04
- EXC 4.47
- 52 Week Low
- ARGX $510.06
- EXC $35.94
- 52 Week High
- ARGX $803.74
- EXC $48.11
- Technical
- Relative Strength Index (RSI)
- ARGX 69.92
- EXC 66.75
- Support Level
- ARGX $698.92
- EXC $44.55
- Resistance Level
- ARGX $803.74
- EXC $45.58
- Average True Range (ATR)
- ARGX 14.72
- EXC 0.66
- MACD
- ARGX 3.56
- EXC 0.22
- Stochastic Oscillator
- ARGX 88.06
- EXC 91.87
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About EXC Exelon Corporation
Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.